In a recent article (3), Norén et al. reported an extensive evaluation of illumigene Clostridium difficile compared with the cell culture cytotoxin B assay (CTBA) and/or toxigenic culture (TC) of cytotoxin-producing C. difficile isolates. The illumigene assay utilizes loop-mediated isothermal DNA amplification (LAMP) technology to detect the pathogenicity locus (PaLoc) of toxigenic Clostridium difficile. The authors reported a sensitivity of 98% (49/50 isolates) and a specificity of 98% (218/222 isolates) for the illumigene assay, using combined CTBA plus TC as the gold standard.
While demonstrating good clinical performance, the authors raised the question of whether the toxin A fragment amplified by the illumigene assay is the optimal target for detecting toxin A-negative/toxin B-positive (A ϩ B Ϫ ) strains. The Clostridium difficile PaLoc segment encodes both the toxin A gene (tcdA) and the toxin B gene (tcdB), has conserved border regions, and is found at the same site on the C. difficile genome for all toxigenic strains. Both the tcdA and the tcdB genes have similar structures consisting of three distinct fragments: a catalytic domain, a putative translocation domain, and a repetitive domain (4). The repetitive regions are prone to homologous recombination resulting in various deletions at the 3Ј ends of the toxin genes. For example, the well-characterized A Ϫ Bϩ strains (toxinotypes VI and VII) and the most frequently occurring strains (toxinotypes VIII and X) all have various deletions at the 3Ј end of the tcdA gene. However, the 5Ј portion of the tcdA gene remains intact for all of these strains. The rationale for the illumigene design is to target the 5Ј region of the tcdA gene that is present in all known A Ϫ B ϩ strains and seems to be more conserved than the tcdB gene (5).
Studies involving well-characterized C. difficile strains were conducted to confirm the primer design. The illumigene assay detected 4 A Ϫ B ϩ and 30 A ϩ B ϩ strains (2). Couturier and She (1) independently confirmed these findings. Again, the illumigene assay was able to detect toxin A ϩ B ϩ strains of toxinotypes 0 (16 strains), III (6 strains), XII (1 strain), and IX/XXIII (1 strain). More importantly, it also amplified toxinotypes VIII (3 strains) and X (1 strain), which are toxin A Ϫ B ϩ (40 non-C. difficile isolates were not detected, including 3 strains of Clostridium sordelii).
In summary, the illumigene C. difficile assay was designed to detect the genetically intact PaLoc region of toxigenic C. difficile regardless of expression phenotypes. 
Authors' Reply
In response to this issue's commentary by Ken Kozak, Chief Technical Officer at Meridian Bioscience, we wish to clarify some of our inherent caution when evaluating new diagnostic tests like illumigene. This promising loop-mediated isothermal DNA amplification (LAMP) assay was rapid and highly sensitive when performed on clinical specimens sent for Clostridium difficile analysis (1). We are well aware of the conserved nature of the target sequence of the toxin A gene (tcdA) (2) that allows for amplification of both truncated tcdA and phenotypically toxin A-negative C. difficile isolates. Our clinical experience to this date does not challenge this view.
From May 2010 to February 2011, we tested 674 clinical fecal specimens sent for C. difficile detection with both LAMP and toxigenic culture (TC) and in part with a cytotoxin B assay (CTBA) as described earlier (1) . One side of the coin is the high sensitivity of a molecular test like LAMP, in which a case of Clostridium difficile infection (CDI) always has to be related to both clinical symptoms and the possibility of asymptomatic nosocomial carriage. Kozak and Elagin question the potential risk of LAMP missing a clinically relevant variant of C. difficile. The referred poster data of 4 toxin A Ϫ B ϩ detected strains is used in an attempt to reduce this concern. Up to this point, we have identified only 5 of 114 TC-positive specimens as LAMP negative by direct testing on feces (sensitivity, 96%). Out of these, 4 of 5 of the cultured C. difficile isolates tested positive in LAMP from the plate, indicating inactivation or possibly inferior sensitivity. A majority (3/4) of these specimens were from patients with a non-CDI type of diarrhea, and in two cases, the patients' specimens were very bloody, which is known to impact test results. One specimen is currently undergoing testing by toxinotyping, since we failed to confirm the cell toxicity of a cultured isolate in CTBA.
In conclusion, LAMP provides the clinician with a very rapid and sensitive CDI diagnostic tool guiding therapy. There is, so far, no sign of false negatives relating to the specific PaLoc tcdA target design. Nevertheless, odd mutations can occur, and culturing of C. difficile isolates enables us not only to clarify phenotype but to test susceptibility and genotype the virulent strains as well.
